BIOXCEL THERAPEUTICS
BioXcel Therapeutics is a clinical-stage biopharmaceutical company focused on drug development that utilizes novel artificial intelligence (AI) to identify the next wave of medicines across neuroscience and immuno-oncology. Its drug re-innovation approach leverages existing approved drugs and/or clinically validated product candidates together with big data and proprietary machine learning algorithms to identify new therapeutic indices. They believe that this differentiated approach has the po... tential to reduce the cost and time of drug development in diseases with substantial unmet medical needs. BXCL501 is a sublingual thin film formulation of the a2a adrenergic receptor agonist dexmedetomidine, or Dex, for acute treatment of agitation resulting from neurological and psychiatric disorders. It intends to utilize the 505(b)(2) pathway for BXCL501, initiated a Phase 1b safety study using the IV formulation of Dex in mild probable Alzheimer's Disease in December 2017, and plans to do the same for schizophrenia patients in the 1H18, with data expected in the 2H18. BXCL701 (formerly Talabostat) is an immuno-oncology agent for the treatment of a rare form of prostate cancer and pancreatic cancer.
BIOXCEL THERAPEUTICS
Industry:
Artificial Intelligence Biopharma Biotechnology Health Care
Founded:
2017-01-01
Address:
Branford, Connecticut, United States
Country:
United States
Website Url:
http://www.bioxceltherapeutics.com
Total Employee:
101+
Status:
Active
Contact:
203 643 8060
Total Funding:
140 M USD
Technology used in webpage:
Viewport Meta IPhone / Mobile Compatible SPF SSL By Default Google Font API Apple Mobile Web Clips Icon WordPress Apache Wordpress Plugins Microsoft Exchange Online
Similar Organizations
Edgewise Therapeutics
Edgewise Therapeutics is a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization.
Current Employees Featured
Vincent J. O'Neill CMO & SVP Clinical Development @ BioXcel Therapeutics
CMO & SVP Clinical Development
2017-07-01
Vimal Mehta Co-Founder & Chief Executive Officer @ BioXcel Therapeutics
Co-Founder & Chief Executive Officer
2017-03-01
Matt Wiley SVP, Chief Commercial Officer @ BioXcel Therapeutics
SVP, Chief Commercial Officer
2022-01-01
Jeffrey Sabados Program Management Support and Government Relations @ BioXcel Therapeutics
Program Management Support and Government Relations
2019-01-01
Founder
Stock Details
Investors List
Qatar Investment Authority
Qatar Investment Authority investment in Post-IPO Debt - BioXcel Therapeutics
Oaktree Capital Management
Oaktree Capital Management investment in Post-IPO Debt - BioXcel Therapeutics
Qatar Investment Authority
Qatar Investment Authority investment in Post-IPO Equity - BioXcel Therapeutics
Oaktree Capital Management
Oaktree Capital Management investment in Post-IPO Equity - BioXcel Therapeutics
Key Employee Changes
Date | New article |
---|---|
2022-01-19 | BioXcel Therapeutics Appoints Matt Wiley Chief Commercial Officer |
Official Site Inspections
http://www.bioxceltherapeutics.com Semrush global rank: 2.05 M Semrush visits lastest month: 10.22 K
- Host name: 20.49.104.33
- IP address: 20.49.104.33
- Location: United States
- Latitude: 37.751
- Longitude: -97.822
- Timezone: America/Chicago
